A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma

Trial Profile

A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs EFT 508 (Primary)
  • Indications Advanced breast cancer; Liver cancer
  • Focus Pharmacodynamics
  • Sponsors Effector Therapeutics
  • Most Recent Events

    • 30 May 2018 Status changed from recruiting to discontinued due to change in focus of the development program
    • 12 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 07 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top